<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Merck & Co Inc (NYSE:MRK) has released new data on its COVID antiviral tablet that suggests it is not as effective as originally hoped. Research from its MOVe-OUT study of the drug, named Molnupiravir, found that it only reduced the risk by roughly 30% in adults at high risk for disease progression.
...read full article on Proactive Investors
